Oruka Therapeutics, Inc. (ORKA)

NGM – Цена в реальном времени. Валюта: USD

90.60

+3.97 (4.58%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

90.58

-0.02 (-0.02%)

После закрытия: Jun 26, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Oruka Therapeutics, Inc. (ORKA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Видео

No Data

Пресс-релизы

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Search stocks

Oruka Therapeutics, Inc. (ORKA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Видео

No Data

Пресс-релизы

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering